menu
    • menu

    Company profile for Aardvark Therapeutics

    NEW Drugs in Dev: 4
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders. Aardvark Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of small molecule therapeutics that activate innate homeostatic pathways for the treatment of disease. Our lead product, ARD-101, is a first-in-class oral composition that is gut restricted, y...
    Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders. Aardvark Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of small molecule therapeutics that activate innate homeostatic pathways for the treatment of disease. Our lead product, ARD-101, is a first-in-class oral composition that is gut restricted, yet conveys systemic effects via activation of gut peptide hormone secretion. Preclinical data demonstrate safety as well as efficacy in a number of metabolic and inflammatory disease models.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Aardvark TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    12707 High Bluff Drive, Suite 200 San Diego, CA 92130-2035
    Telephone
    Telephone
    +1 616-3370-224
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://aardvarktherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    PBP World Meeting

    Not Confirmed

    envelop Contact Supplier

    PBP World Meeting

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aardvark Pauses Ph. 3 Hunger Trial Over 'Cardiac Observations'
    Aardvark Pauses Ph. 3 Hunger Trial Over 'Cardiac Observations'

    02 Mar 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/aardvark-pauses-phase-3-metabolic-drug-study-over-cardiac-observations-sinking-sock

    FIERCE BIOTECH
    02 Mar 2026
    Share Share
    Aardvark Voluntary Pauses HERO Trial in Prader-Willi Syndrome
    Aardvark Voluntary Pauses HERO Trial in Prader-Willi Syndrome

    27 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/27/3246791/0/en/Aardvark-Therapeutics-Announces-Voluntary-Pause-of-Phase-3-HERO-Trial-in-Prader-Willi-Syndrome.html

    GLOBENEWSWIRE
    27 Feb 2026
    Share Share
    Aardvark Therapeutics Announces Inducement Grants
    Aardvark Therapeutics Announces Inducement Grants

    13 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/13/3238066/0/en/Aardvark-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    13 Feb 2026
    Share Share
    Aardvark Sets Up New US Subsidiary; Bryan Jones Named CEO
    Aardvark Sets Up New US Subsidiary; Bryan Jones Named CEO

    12 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/12/3237146/0/en/Aardvark-Therapeutics-Announces-Establishment-of-New-U-S-Subsidiary-to-Support-Development-of-Its-Dermatology-Pipeline-Bryan-Jones-Named-Chief-Executive-Officer.html

    GLOBENEWSWIRE
    12 Feb 2026
    Share Share
    Aardvark Therapeutics Announces Leadership Appointments
    Aardvark Therapeutics Announces Leadership Appointments

    12 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/12/3237145/0/en/Aardvark-Therapeutics-Announces-Leadership-Appointments.html

    GLOBENEWSWIRE
    12 Feb 2026
    Share Share
    Aardvark Submits FDA & IRB-Approved Trial Protocol FOR ARD-101
    Aardvark Submits FDA & IRB-Approved Trial Protocol FOR ARD-101

    10 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/10/3235262/0/en/Aardvark-Therapeutics-Announces-FDA-Submission-and-IRB-Approval-of-Amended-Trial-Protocol-for-Lead-Candidate-ARD-101-Expanding-Eligibility-in-Phase-3-Study-of-Prader-Willi-Syndrome.html

    GLOBENEWSWIRE
    10 Feb 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search